Juvenile Idiopathic Arthritis

Single-Dose Prefilled Autoinjector for Actemra Approved

Single-Dose Prefilled Autoinjector for Actemra Approved

By

Genentech announced that the FDA has approved ACTPen autoinjector for Actemra as a new formulation for adults with moderate to severe active RA.

Higher Biologic Drug Survival in JIA With Younger Age at Treatment Initiation

Higher Biologic Drug Survival in JIA With Younger Age at Treatment Initiation

By

Rates of biologic drug survival and suspension by remission were both higher in those who initiated biologic treatment at <16 years.

Rituximab May Be Effective in Children With Treatment-Resistant Juvenile Idiopathic Arthritis

Rituximab May Be Effective in Children With Treatment-Resistant Juvenile Idiopathic Arthritis

By

Rituximab may be an effective treatment option for many patients with juvenile idiopathic arthritis who did not respond to other therapies.

Determining Risk for New-Onset Uveitis in Juvenile Idiopathic Arthritis

Determining Risk for New-Onset Uveitis in Juvenile Idiopathic Arthritis

By

Researchers sought to quantify the annual incidence of new-onset uveitis following JIA diagnosis and identify associated risk factors.

Psychological Flexibility Improves Resilience in Children With Juvenile Idiopathic Arthritis and Their Parents

Psychological Flexibility Improves Resilience in Children With Juvenile Idiopathic Arthritis and Their Parents

By

Psychological flexibility in children with juvenile idiopathic arthritis and in their parents may represent resilience factors for dealing with pain and disability associated with the condition.

Canakinumab Treatment Led to Substantial Glucocorticoid Reduction in JIA

Canakinumab Treatment Led to Substantial Glucocorticoid Reduction in JIA

By

Researchers evaluated the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis.

Original vs Expanded Disease Activity Scoring System in JIA Examined

Original vs Expanded Disease Activity Scoring System in JIA Examined

By

For a more precise assessment of disease activity and treatment effectiveness in individuals with JIA, inclusion of MCP joints should be considered in the scoring system.

Actemra SC Approved to Treat Active Systemic JIA

Actemra SC Approved to Treat Active Systemic JIA

By

The FDA has approved Actemra SC for the treatment of active systemic JIA alone or in combination with methotrexate in patients ≥2 years old.

Examining Gaps in Mental Health Care Among Youth With Juvenile Rheumatic Disease

Examining Gaps in Mental Health Care Among Youth With Juvenile Rheumatic Disease

By

There is an unmet need for mental health interventions that address illness-related issues affecting youth with rheumatologic conditions.

Clinical Assessment of Juvenile Idiopathic Arthritis: Predicting Unfavorable Long-Term Outcomes

Clinical Assessment of Juvenile Idiopathic Arthritis: Predicting Unfavorable Long-Term Outcomes

By

Prediction models of outcomes in juvenile idiopathic arthritis have acceptable precision and require only readily available baseline variables.

Clinical Correlates of JIA Relapse After Biologic Therapy Discontinuation

Clinical Correlates of JIA Relapse After Biologic Therapy Discontinuation

By

The investigators sought to evaluate the time patients were in remission after discontinuing biologic therapy for the treatment of JIA.

Actemra SC Approved to Treat Polyarticular Juvenile Idiopathic Arthritis

Actemra SC Approved to Treat Polyarticular Juvenile Idiopathic Arthritis

By

The FDA has approved the subcutaneous formulation of Actemra for the treatment of active polyarticular juvenile idiopathic arthritis.

Depressive Symptoms Predict Future Pain, Disability in Adolescent JIA

Depressive Symptoms Predict Future Pain, Disability in Adolescent JIA

By

Baseline depressive symptoms were associated with pain and disability in adolescents with juvenile idiopathic arthritis.

Efficacy, Safety of Adalimumab vs Infliximab in JIA-Associated Uveitis

Efficacy, Safety of Adalimumab vs Infliximab in JIA-Associated Uveitis

By

Researchers evaluated the safety and efficacy of adalimumab and infliximab in the treatment of juvenile idiopathic arthritis-associated uveitis in patients treated for at least 2 years.

Treatment Targets in JIA: Comparing Definitions of Clinically Inactive Disease

Treatment Targets in JIA: Comparing Definitions of Clinically Inactive Disease

By

Investigators aimed to examine the use of treatment targets in juvenile idiopathic arthritis in terms of joint limitations, functional ability, psychosocial health, and pain levels.

Managing Uveitis in Juvenile Idiopathic Arthritis: Consensus-Based Recommendations

Managing Uveitis in Juvenile Idiopathic Arthritis: Consensus-Based Recommendations

By

The SHARE initiative has provided recommendations for the diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis.

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

Clinical Features Identified in Enthesitis-Related Juvenile Idiopathic Arthritis, Juvenile Spondyloarthritis

By

Results confirm that juvenile spondyloarthritis is characterized by its peripheral pattern at disease onset, with peripheral arthritis and enthesitis.

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

Genetic Risk Loci Found Within Disease Phenotypes Including SLE, JIA

The Epstein-Barr virus EBNA2 protein and many coclustering human transcription factors occupied nearly half of SLE risk loci.

Ultrasound Not Predictive of Disease Flares for Inactive Juvenile Idiopathic Arthritis

Ultrasound Not Predictive of Disease Flares for Inactive Juvenile Idiopathic Arthritis

By

Abnormal ultrasound findings were common in patients with juvenile idiopathic arthritis with clinically inactive disease.

Flare Risk Examined in Juvenile Idiopathic Arthritis After Anti-TNF Therapy Discontinuation

Flare Risk Examined in Juvenile Idiopathic Arthritis After Anti-TNF Therapy Discontinuation

By

Researchers sought to determine the predictors of disease flare after anti-TNF therapy discontinuation in children with polyarticular forms of juvenile idiopathic arthritis with sustained clinically inactive disease.

Examining the Role of Neutrophils in Systemic-Onset Juvenile Idiopathic Arthritis

Examining the Role of Neutrophils in Systemic-Onset Juvenile Idiopathic Arthritis

By

High neutrophil counts decreased after initiation of recombinant interleukin-1 receptor agonist therapy in systemic-onset juvenile idiopathic arthritis.

TNF Inhibitor Therapy Unlikely to Affect Malignancy Risk in Children

TNF Inhibitor Therapy Unlikely to Affect Malignancy Risk in Children

By

Children with juvenile idiopathic arthritis, pediatric inflammatory bowel disease, and pediatric plaque psoriasis had an increased incidence of childhood malignancies, regardless of TNFi exposure.

Juvenile Idiopathic Arthritis: Baseline Ultrasound Abnormalities May Predict Relapse

Juvenile Idiopathic Arthritis: Baseline Ultrasound Abnormalities May Predict Relapse

By

Abnormality on an ultrasound examination significantly increased the risk for flare in patients with juvenile idiopathic arthritis.

Improving Pediatric Rheumatic Disease Care With Consensus-Based Treatment Plans

Improving Pediatric Rheumatic Disease Care With Consensus-Based Treatment Plans

By

The goal of consensus treatment plans is to drive a cycle of innovation and replacement that allows the addition of new treatments and the removal of unused or ineffective strategies.

More Severe Disease Found in Juvenile Myositis With Anti-NT5C1A Autoantibodies

More Severe Disease Found in Juvenile Myositis With Anti-NT5C1A Autoantibodies

By

Autoantibodies that recognize cytosolic 5′-nucleotidase 1A were detected in about 25% of patients with juvenile myositis and juvenile idiopathic arthritis.

Choosing a Biologic Therapy for JIA: Etanercept vs Tocilizumab vs IL-1 Inhibitors

Choosing a Biologic Therapy for JIA: Etanercept vs Tocilizumab vs IL-1 Inhibitors

By

Treatment response was most significant in patients taking either tocilizumab or an interleukin-1 inhibitor.

Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate

Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate

By

Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.

Juvenile Idiopathic Arthritis Disease Activity Low but Stable During Pregnancy

Juvenile Idiopathic Arthritis Disease Activity Low but Stable During Pregnancy

By

An increase in disease activity 6 weeks postpartum suggests the need for tight follow-up of women with juvenile idiopathic arthritis.

Fluorescence Optical Imaging for Diagnosis of Pediatric Rheumatologic Conditions

Fluorescence Optical Imaging for Diagnosis of Pediatric Rheumatologic Conditions

By

Chronic inflammatory rheumatologic diseases benefit from early anti-inflammatory treatment; however, interdisciplinary approaches may be necessary for identifying and managing noninflammatory joint pain.

Clinical Juvenile Arthritis Disease Activity Score Use in Treat-to-Target Therapy

Clinical Juvenile Arthritis Disease Activity Score Use in Treat-to-Target Therapy

By

The objective of this study is to determine whether the JADAS or cJADAS would accurately predict patients with JIA in need of treatment escalation to anti-TNF after starting MTX.

Sign Up for Free e-newsletters